Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Jefferies Financial Group Inc.

Key Points

• Jefferies Financial Group increased its stake in Alnylam by 98.3% in Q3, owning 16,542 shares valued at about $7.54 million after adding 8,200 shares.
• Alnylam missed quarterly expectations with EPS of $1.25 versus the $1.43 consensus and revenue of $1.10B versus $1.16B, although revenue rose 84.9% year‑over‑year.
• Insiders sold 53,923 shares (~$18.07M) over the last quarter while institutional ownership is high at 92.97%; analysts rate the stock a Moderate Buy with a consensus target of $477.96.

Jefferies Financial Group Inc. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,542 shares of the biopharmaceutical company's stock after acquiring an additional 8,200 shares during the period. Jefferies Financial Group Inc.'s holdings in Alnylam Pharmaceuticals were worth $7,543,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $32,000. Finally, ORG Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 33 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.9%

ALNY opened at $323.53 on Tuesday. The stock's 50 day moving average price is $350.74 and its 200 day moving average price is $413.17. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The stock has a market cap of $42.91 billion, a P/E ratio of 189.20 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the firm posted ($0.65) EPS. The company's revenue was up 84.9% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of recent research reports. Freedom Capital raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, February 17th. Raymond James Financial reaffirmed an "outperform" rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. HC Wainwright reissued a "buy" rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an "outperform" rating for the company in a research report on Tuesday, January 20th. Finally, Bank of America restated a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $477.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,775 shares of the company's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the sale, the executive vice president owned 23,406 shares of the company's stock, valued at $7,483,834.44. This represents a 7.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares of the company's stock, valued at $21,059,048.45. This represents a 3.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 53,923 shares of company stock valued at $18,072,087. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.